Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US-2015343056-A1 · Dec 3, 2015 · US
Discovery and applications of the proteolytic function of N-terminal acetylation of cellular proteins
US8999896B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8999896-B2 |
| Application number | US-201113007546-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2011 |
| Priority date | Jan 15, 2010 |
| Publication date | Apr 7, 2015 |
| Grant date | Apr 7, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Screening assays that allow for the identification of agents that modulate the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway are provided. Also provided are methods of using an agent that modulates the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway to increase or decrease protein degradation in a cell, and to modulate physiologic and pathologic associated with N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of identifying an agent that modulates N α -terminal acetyl transferase-mediated N-end rule pathway-mediated acetylation of an amino terminal (N-terminal) Met, Ala, Val, Ser, Thr, Cys, Gly, or Pro residue of a peptide, comprising: a) contacting at least one sample comprising a peptide having an N-terminal Met, Ala, Val, Ser, Thr, Cys, Gly, or Pro residue of the peptide, wherein the peptide comprises an N-terminal portion of a fusion protein and wher…
Assignees
Inventors
Classifications
- C12Q1/48Primary
Chemistry & Metallurgy · mapped topic
Physics · mapped topic
Physics · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8999896B2 cover?
- Screening assays that allow for the identification of agents that modulate the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway are provided. Also provided are methods of using an agent that modulates the activity of N-terminal acetylation of a polypeptide and the Doa10 branch of the N-end rule pathway to increase or decrease protein degradation…
- Who is the assignee on this patent?
- Hwang Cheol-Sang, Shemorry Anna, Varshavsky Alexander, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).